Does treatment with N-butyl cyanoacrylate embolization protect against hemorrhage in cerebral arteriovenous malformations?

Arq Neuropsiquiatr. 2005 Mar;63(1):34-9. doi: 10.1590/s0004-282x2005000100007. Epub 2005 Apr 13.

Abstract

Objective: To assess the role of this procedure to prevent hemorrhage in cerebral arteriovenous malformations (cAVM).

Method: Between 1992 and 2000, we studied 104 patients submitted to embolization as the main treatment. Patients were followed until hemorrhage or death.

Results: Follow-up ranged from 1.6 months to 8 years. The most frequent presentations were hemorrhage (50%) and seizures (38%). In addition, 40% were small (<30 mm); 56% were medium (30-60 mm). Obliteration was < or =1/3 in 11% of the cases; from 1/3 to < or = 2/3 in 49%; >2/3 in 36%; complete in 5%. The risk of death was 1%/year, and of bleeding, 5.4%/year. Presentation with hemorrhage and low obliteration rate were the main factors associated with hemorrhage.

Conclusion: cAVM embolization provides limited protection against hemorrhage with obliteration rates below 2/3. Presentation with hemorrhage is the main factor for predicting hemorrhage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Embolization, Therapeutic*
  • Enbucrilate / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Intracranial Arteriovenous Malformations / therapy*
  • Intracranial Hemorrhages / prevention & control*
  • Male
  • Middle Aged
  • Risk Factors
  • Treatment Outcome

Substances

  • Enbucrilate